ChandraKota,Ph.D.

1.5K posts

ChandraKota,Ph.D. banner
ChandraKota,Ph.D.

ChandraKota,Ph.D.

@RadOnc_AI

Technology for Humans #cancer #Radonc #Medphys

Katılım Mart 2019
175 Takip Edilen365 Takipçiler
ChandraKota,Ph.D. retweetledi
Jeff Ryckman
Jeff Ryckman@jryckman3·
Amazing to connect with the incredible @TargetingCancer team & friends at #ASTRO24! 🌟 Despite ~2% of global onc research spend going to #RadOnc, RT is saving lives every day. Proud to be part of the global push to raise awareness for its vital role in cancer treatment! 💪🌍
Jeff Ryckman tweet mediaJeff Ryckman tweet mediaJeff Ryckman tweet media
English
1
15
52
7.6K
Matt Spraker
Matt Spraker@SprakerMDPhD·
A cool paper that was shared with me by a listener about... The On Table Adaptive Contouring APRT Credentialed through in-house training, no degree. And a payoff of significant time savings for physicians and the department. (Research led by... an APRT, ay @cameronatharp)
Matt Spraker tweet media
The Accelerators Podcast ☢️@AcceleratorsRO

A surprise TAP for your trip home 😍 Radiation therapist @cameronatharp joins TAP to host Shaun Caldwell, a therapist, educator, and researcher. We discuss the nascent Advanced Practice Radiation Therapist (APRT) role in the US and beyond. #RadOnc

English
3
0
9
2.1K
Jordan Johnson
Jordan Johnson@JordanJ65544091·
@SprakerMDPhD @cameronatharp @adapthyun @JoshuaSchiffMD @samsonpp As long as you are willing to give up something then it works. RO, is exactly like Anesthesiology and Radiology when you look at these angles. Every site is very different, and the inward consolidation will continue. Value is by tasks association unfortunately.
English
3
0
3
223
ChandraKota,Ph.D. retweetledi
John Christodouleas
John Christodouleas@Xristodouleas·
We argued: 1. Public and private payers aiming to improve radiotherapy access while controlling costs should incentivize SBRT, yet most create disincentives.   2. No one owns a patent on radiotherapy. The lack of resources directed toward studying its optimal delivery through clinical research is a market failure. Governments must step in to address the disparity between radiotherapy’s critical role in cancer care and the lack of research funding.   3. The latest Lancet Oncology Commission is another tremendous resource for anyone interested in radiotherapy at a systems level. @TheLancetOncol @ASTRO_org @ESTRO_RT @Elekta @ARPA_H
The Lancet Oncology@TheLancetOncol

Linked to Lancet Oncology Commission on #radiotherapy and #theranostics: Comment: Focus where it matters: turning insights into advocacy —@Xristodouleas, @ThereseSLinde, & Gustaf Salford @Elekta thelancet.com/journals/lanon…

English
1
5
25
3.4K
ChandraKota,Ph.D.
ChandraKota,Ph.D.@RadOnc_AI·
@EliasKress It’s a policy and reimbursement issue. When reimbursement is tied to outcomes, it will spur innovation in surgical and radiation oncology, and newer non pharmacological interventions.
English
0
0
0
215
Eli
Eli@EliasKress·
radiation therapy is used in over 50% of all cancer cases due to its efficacy as a curative treatment and improved quality of life over surgery, yet the field sees a meager 3% of global oncology research budget. it’s time to change this
English
1
21
52
5.1K
ChandraKota,Ph.D.
ChandraKota,Ph.D.@RadOnc_AI·
@PCFnews Some level of medical literacy is so important these days.. so that folks can learn when they are healthy and be able to make informed decisions as patients when needed.
English
1
0
1
110
ChandraKota,Ph.D. retweetledi
Prostate Cancer Foundation
Mike Milken has dedicated himself to raising prostate cancer awareness nationwide. His passion stems from his own battle with the disease and a desire to help others walking a similar path. Join our team for the 29th season of the #HomeRunChallenge bit.ly/3QzgjE8
Prostate Cancer Foundation tweet media
English
1
4
12
2.3K
Matt Spraker
Matt Spraker@SprakerMDPhD·
Poll and opinion request, inspired by my awesome dosimetrists. Should a #RadOnc be using a target volume Dmin goal in their directives? Bonus points for informative comments! @jryckman3
English
7
1
2
7.6K
ChandraKota,Ph.D.
ChandraKota,Ph.D.@RadOnc_AI·
@JordanJ65544091 @toddscarbrough There is no reason for MDs or physicists to do planning very efficiently, with semi automated TPS. Autocontouring, knowledge based planning, etc. Happens in the rest of the world.
English
1
0
3
234
Jordan Johnson
Jordan Johnson@JordanJ65544091·
When the pressure cooker increases. Apparently, a medical dosimetry salary survey was published, and the max end is $240k. We have been told that there were chat forums encouraging them to inflate wages on the survey. Now, they are asking for $40-$50k raises. Not all of them obviously, but they do understand how this works and what it creates. Economics 101. This will have a very negative impact if it becomes a wave. will lead to faster push for software automation and finding cheaper dosimetrist. I added them at 180k so you can see the impact. @SprakerMDPhD @SameerKeoleMD @srob61 @StrasserMD @toddscarbrough @5_utr @subatomicdoc @wdavidlindsay @seanmmcbride
Jordan Johnson tweet media
English
8
1
1
3.6K
ChandraKota,Ph.D. retweetledi
Daniel E Spratt
Daniel E Spratt@DrSpratticus·
As long as the community, which often is medoncs discussing radiopharm, as ‘dose’ we are doomed to not make progress. Pains me this basic rad physics 101 terminology is not even known. Now nuc med, who 100% knows the difference, is saying ‘dose’ to over simplify, when they know it is ‘activity’. End of the day this is ionizing radiotherapy and dose to tumor matters for cell kill. Giving same activity for someone with 2 bone Mets vs 100 bone Mets is giving very different doses to normal and tumor. These are not simple drugs like ARPI or chemo. @US_FDA needs to have greater flexibility for more personalized activity and dosimetry. I encourage @DrMHofman @thomashopemd Herrmann, Emmett, and others to force the clinical community to adapt to appropriate terminology so we can make progress. If the ordering providers of RLT can’t understand this difference they shouldn’t be giving it.
Pierre Blanchard, MD@PBlanchardMD

Great comments by @DrSpratticus on PSMA therapy 1. Should be treated as radiation treatment and not drug 2. Activity (not dose) should be adapted to tumor burden to ensure proper efficacy 3. Impact of fractionation needs to be studied #APCCC24

Lugano, Switzerland 🇨🇭 English
9
18
91
22.2K
ChandraKota,Ph.D. retweetledi
Shankar Siva
Shankar Siva@_ShankarSiva·
What I learned in 🇨🇱 today … $5mill = one #radiotherapy machine☢️, can treat 10k patients. $5mill = 135 patients worth of trastuzumab. 🧐 @TheLancetOncol - tinyurl.com/6bry9a2a “an essential pillar in multi-D oncology…an inexpensive modality” - 👏🏽 well said @TargetingCancer
Shankar Siva tweet media
English
9
87
224
34.7K